Summit Therapeutics PLC (SMMT) - Net Assets
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has net assets worth $414.01 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($491.31 Million) and total liabilities ($77.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SMMT tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $414.01 Million |
| % of Total Assets | 84.27% |
| Annual Growth Rate | 44.78% |
| 5-Year Change | 692.04% |
| 10-Year Change | N/A |
| Growth Volatility | 3940.35 |
Summit Therapeutics PLC - Net Assets Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. See Summit Therapeutics PLC liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Summit Therapeutics PLC (2003–2025)
The table below shows the annual net assets of Summit Therapeutics PLC from 2003 to 2025. For live valuation and market cap data, see market value of Summit Therapeutics PLC.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $488.98 Million | +57.41% |
| 2024-12-31 | $310.64 Million | +405.26% |
| 2023-12-31 | $61.48 Million | -40.45% |
| 2022-12-31 | $103.25 Million | +67.24% |
| 2021-12-31 | $61.74 Million | +5.79% |
| 2020-12-31 | $58.36 Million | -4.51% |
| 2019-12-31 | $61.12 Million | +9.55% |
| 2018-12-31 | $55.79 Million | +299.13% |
| 2017-12-31 | $13.98 Million | +420.14% |
| 2016-12-31 | $-4.37 Million | -114.51% |
| 2015-12-31 | $30.10 Million | +54.11% |
| 2014-12-31 | $19.53 Million | +148.63% |
| 2013-12-31 | $7.85 Million | +74.43% |
| 2012-12-31 | $4.50 Million | +19.19% |
| 2011-12-31 | $3.78 Million | -35.09% |
| 2010-12-31 | $5.82 Million | -55.99% |
| 2009-12-31 | $13.22 Million | +7.28% |
| 2008-12-31 | $12.33 Million | -77.20% |
| 2007-12-31 | $54.08 Million | +34.82% |
| 2006-12-31 | $40.11 Million | +71.60% |
| 2005-12-31 | $23.38 Million | -11.88% |
| 2004-12-31 | $26.53 Million | +18540.62% |
| 2003-12-31 | $142.31K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Summit Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 170259290500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.75 Million | 1.18% |
| Other Comprehensive Income | $-1.89 Million | -0.39% |
| Other Components | $2.19 Billion | 447.41% |
| Total Equity | $488.98 Million | 100.00% |
Summit Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Summit Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AAON Inc
NASDAQ:AAON
|
$10.92 Billion |
|
Subsea 7 S.A.
OL:SUBC
|
$10.93 Billion |
|
CACI International Inc
NYSE:CACI
|
$10.93 Billion |
|
Assurant Inc
NYSE:AIZ
|
$10.94 Billion |
|
Revvity Inc.
NYSE:RVTY
|
$10.91 Billion |
|
China Railway Construction Corp Ltd
SHG:601186
|
$10.91 Billion |
|
American Financial Group, Inc.
NYSE:AFG
|
$10.91 Billion |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
$10.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Summit Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 310,644,639 to 488,979,537, a change of 178,334,898 (57.4%).
- Net loss of 1,079,586,000 reduced equity.
- New share issuances of 604,565,000 increased equity.
- Other comprehensive income decreased equity by 59,166.
- Other factors increased equity by 653,415,064.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.08 Billion | -220.78% |
| Share Issuances | $604.57 Million | +123.64% |
| Other Comprehensive Income | $-59.17K | -0.01% |
| Other Changes | $653.42 Million | +133.63% |
| Total Change | $- | 57.41% |
Book Value vs Market Value Analysis
This analysis compares Summit Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1880.85x to 21.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $0.01 | $14.07 | x |
| 2004-12-31 | $1.13 | $14.07 | x |
| 2005-12-31 | $0.75 | $14.07 | x |
| 2006-12-31 | $1.10 | $14.07 | x |
| 2007-12-31 | $1.13 | $14.07 | x |
| 2008-12-31 | $0.23 | $14.07 | x |
| 2009-12-31 | $0.20 | $14.07 | x |
| 2010-12-31 | $0.15 | $14.07 | x |
| 2011-12-31 | $0.02 | $14.07 | x |
| 2012-12-31 | $0.28 | $14.07 | x |
| 2013-12-31 | $0.38 | $14.07 | x |
| 2014-12-31 | $0.49 | $14.07 | x |
| 2015-12-31 | $0.51 | $14.07 | x |
| 2016-12-31 | $-0.07 | $14.07 | x |
| 2017-12-31 | $0.21 | $14.07 | x |
| 2018-12-31 | $0.65 | $14.07 | x |
| 2019-12-31 | $1.86 | $14.07 | x |
| 2020-12-31 | $0.84 | $14.07 | x |
| 2021-12-31 | $0.67 | $14.07 | x |
| 2022-12-31 | $0.53 | $14.07 | x |
| 2023-12-31 | $0.10 | $14.07 | x |
| 2024-12-31 | $0.43 | $14.07 | x |
| 2025-12-31 | $0.65 | $14.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Summit Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -220.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-220.78%) is below the historical average (-103.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -29.49% | -2300.60% | 0.01x | 1.03x | $-56.19K |
| 2004 | -0.33% | -40.71% | 0.01x | 1.01x | $-2.74 Million |
| 2005 | -8.11% | -200.02% | 0.04x | 1.11x | $-4.23 Million |
| 2006 | -14.77% | -292.11% | 0.04x | 1.16x | $-9.94 Million |
| 2007 | -37.22% | -334.07% | 0.09x | 1.28x | $-25.54 Million |
| 2008 | -261.93% | -12109.63% | 0.01x | 1.63x | $-33.52 Million |
| 2009 | -40.39% | -1769.24% | 0.02x | 1.39x | $-6.66 Million |
| 2010 | -127.52% | -1004.60% | 0.09x | 1.38x | $-8.00 Million |
| 2011 | -111.97% | -378.97% | 0.18x | 1.62x | $-4.61 Million |
| 2012 | -93.82% | -222.96% | 0.27x | 1.54x | $-4.68 Million |
| 2013 | -77.57% | -330.42% | 0.15x | 1.53x | $-6.88 Million |
| 2014 | -58.29% | -602.97% | 0.06x | 1.50x | $-13.34 Million |
| 2015 | -66.91% | -1571.98% | 0.04x | 1.19x | $-23.15 Million |
| 2016 | 0.00% | -899.45% | 0.05x | 0.00x | $-20.93 Million |
| 2017 | -144.21% | -142.28% | 0.19x | 5.46x | $-21.56 Million |
| 2018 | 19.48% | 19.04% | 0.72x | 1.43x | $5.29 Million |
| 2019 | 8.17% | 11.61% | 0.57x | 1.23x | $-1.12 Million |
| 2020 | -66.03% | -6127.56% | 0.01x | 1.29x | $-44.37 Million |
| 2021 | -139.54% | -4762.13% | 0.02x | 1.36x | $-92.32 Million |
| 2022 | -63.12% | -11174.75% | 0.00x | 5.24x | $-75.49 Million |
| 2023 | -784.57% | 0.00% | 0.00x | 2.61x | $-488.52 Million |
| 2024 | -56.91% | 0.00% | 0.00x | 1.12x | $-207.84 Million |
| 2025 | -220.78% | 0.00% | 0.00x | 1.14x | $-1.13 Billion |
Industry Comparison
This section compares Summit Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Summit Therapeutics PLC (SMMT) | $414.01 Million | -29.49% | 0.19x | $10.92 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more